When levels of miR-342 drop, the E2F genetic pathway is unleashed, signaling disseminated cancer cells to begin the rapid multiplication required to form tumors. This mechanism serves as a terrifying catalyst for triple-negative breast cancer, a subtype that has historically defied the precision
A strategic partnership with a pharmaceutical firm allows Outer Biosciences to investigate the biological mechanisms behind skin rashes caused by cancer treatments. This initiative marks a significant departure from traditional dermatological research, signaling a move toward high-precision,
By integrating a selectively permeable endothelial lining, this new technology forces cancer cells to demonstrate their ability to traverse vessel walls. This breakthrough represents a monumental shift in oncology, moving away from the static culture plates and animal models that have dominated
Advanced algorithms are now capable of correlating visual cellular patterns on pathology slides with specific gene-expression profiles linked to aggressive disease. This breakthrough in digital pathology allows clinicians to look beyond the surface level of tissue samples to understand the
The strategic alliance between Merck and the Sarah Cannon Research Institute aims to transform oncology research by deploying a network of over 200 locations and 1,500 oncology physicians. This massive undertaking addresses a fundamental imbalance in modern medicine: while nearly eighty-five
The SOHO-01 trial results highlight that gastrointestinal and skin-related issues such as diarrhea and rash are the most common side effects, which are generally considered manageable by clinicians. On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare reached a landmark decision by